Role of Epigenetic Modifications in Inhibitory Immune Checkpoints in Cancer Development and Progression
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Role of Epigenetic Modifications in Inhibitory Immune Checkpoints in Cancer Development and Progression
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 11, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2020-07-14
DOI
10.3389/fimmu.2020.01469
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A novel IFNα-induced long noncoding RNA negatively regulates immunosuppression by interrupting H3K27 acetylation in head and neck squamous cell carcinoma
- (2020) Hailong Ma et al. Molecular Cancer
- Transcriptomic profiling disclosed the role of DNA methylation and histone modifications in tumor-infiltrating myeloid-derived suppressor cell subsets in colorectal cancer
- (2020) Varun Sasidharan Nair et al. Clinical Epigenetics
- HDAC6 selective inhibition of melanoma patient T-cells augments anti-tumor characteristics
- (2019) Andressa S. Laino et al. Journal for ImmunoTherapy of Cancer
- Overexpressed histone acetyltransferase 1 regulates cancer immunity by increasing programmed death-ligand 1 expression in pancreatic cancer
- (2019) Ping Fan et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Targeting epigenetics for cancer therapy
- (2019) Jong Woo Park et al. ARCHIVES OF PHARMACAL RESEARCH
- Epigenetics in cancer therapy and nanomedicine
- (2019) Annalisa Roberti et al. Clinical Epigenetics
- The Potential for microRNA Therapeutics and Clinical Research
- (2019) Johora Hanna et al. Frontiers in Genetics
- Immune checkpoints in the tumor microenvironment
- (2019) Salman M. Toor et al. SEMINARS IN CANCER BIOLOGY
- Acquired resistance to cancer immunotherapy: Role of tumor-mediated immunosuppression
- (2019) Reem Saleh et al. SEMINARS IN CANCER BIOLOGY
- Low Expression of miR-424-3p is Highly Correlated with Clinical Failure in Prostate Cancer
- (2019) E. Richardsen et al. Scientific Reports
- Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells
- (2019) Tessa Knox et al. Scientific Reports
- Drugs Targeting Epigenetic Modifications and Plausible Therapeutic Strategies Against Colorectal Cancer
- (2019) Srinivas Patnaik et al. Frontiers in Pharmacology
- Treg-mediated acquired resistance to immune checkpoint inhibitors
- (2019) Reem Saleh et al. CANCER LETTERS
- LncRNA SNHG14/miR-5590-3p/ZEB1 positive feedback loop promoted diffuse large B cell lymphoma progression and immune evasion through regulating PD-1/PD-L1 checkpoint
- (2019) Lina Zhao et al. Cell Death & Disease
- The Regulatory Role of MicroRNAs in Breast Cancer
- (2019) Hui-Yi Loh et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load
- (2019) Hyunchul Jung et al. Nature Communications
- Immunological Effects of Epigenetic Modifiers
- (2019) Lucillia Bezu et al. Cancers
- Immune Checkpoints in Circulating and Tumor-Infiltrating CD4+ T Cell Subsets in Colorectal Cancer Patients
- (2019) Salman M. Toor et al. Frontiers in Immunology
- Lymphocyte-Activation Gene-3 Expression and Prognostic Value in Neoadjuvant-Treated Triple-Negative Breast Cancer
- (2018) Yunxuan Wang et al. Journal of Breast Cancer
- EZH2 promotes hepatocellular carcinoma progression through modulating miR-22/galectin-9 axis
- (2018) Shaofei Chen et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Histone deacetylase (HDAC) inhibitor ACY241 enhances anti-tumor activities of antigen-specific central memory cytotoxic T lymphocytes against multiple myeloma and solid tumors
- (2018) Jooeun Bae et al. LEUKEMIA
- Histone Methyltransferase EZH2: A Therapeutic Target for Ovarian Cancer
- (2018) Bayley A. Jones et al. MOLECULAR CANCER THERAPEUTICS
- High CTLA-4 expression correlates with poor prognosis in thymoma patients
- (2018) Giorgio Santoni et al. Oncotarget
- DNA methylation and repressive H3K9 and H3K27 trimethylation in the promoter regions of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, and PD-L1 genes in human primary breast cancer
- (2018) Varun Sasidharan Nair et al. Clinical Epigenetics
- Highly elevated soluble Tim-3 levels correlate with increased hepatocellular carcinoma risk and poor survival of hepatocellular carcinoma patients in chronic hepatitis B virus infection
- (2018) Fang Li et al. Cancer Management and Research
- PD-1 ( PDCD1 ) Promoter Methylation Is a Prognostic Factor in Patients With Diffuse Lower-Grade Gliomas Harboring Isocitrate Dehydrogenase ( IDH ) Mutations
- (2018) Lea Kristin Röver et al. EBioMedicine
- Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations
- (2018) Judith A. Seidel et al. Frontiers in Oncology
- DNA methylation and repressive histones in the promoters of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, PD-L1, and galectin-9 genes in human colorectal cancer
- (2018) Varun Sasidharan Nair et al. Clinical Epigenetics
- Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation
- (2018) Jacob O'Brien et al. Frontiers in Endocrinology
- TIM-3, a promising target for cancer immunotherapy
- (2018) Yayi He et al. OncoTargets and Therapy
- DNA methylation of immune checkpoints in the peripheral blood of breast and colorectal cancer patients
- (2018) Asma A. Elashi et al. OncoImmunology
- Soluble immune checkpoints in cancer: production, function and biological significance
- (2018) Daqian Gu et al. Journal for ImmunoTherapy of Cancer
- Noncoding RNAs and immune checkpoints-clinical implications as cancer therapeutics
- (2017) Maria A. Smolle et al. FEBS Journal
- Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells
- (2017) Varun Sasidharan Nair et al. IMMUNOLOGY AND CELL BIOLOGY
- Epigenetic regulation of immune checkpoints: another target for cancer immunotherapy?
- (2017) Mahmoud A Ali et al. Immunotherapy
- High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer
- (2017) Yusuke Okuma et al. LUNG CANCER
- Cell cycle-targeting microRNAs promote differentiation by enforcing cell-cycle exit
- (2017) Tobias Otto et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Correlation between messenger RNA expression and protein expression of immune checkpoint–associated molecules in bladder urothelial carcinoma: A retrospective study
- (2017) Constance Le Goux et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- PD-L1 (CD274) and PD-L2 (PDCD1LG2) promoter methylation is associated with HPV infection and transcriptional repression in head and neck squamous cell carcinomas
- (2017) Alina Franzen et al. Oncotarget
- PDCD1 (PD-1) promoter methylation predicts outcome in head and neck squamous cell carcinoma patients
- (2017) Diane Goltz et al. Oncotarget
- HDAC inhibition potentiates immunotherapy in triple negative breast cancer
- (2017) Manuela Terranova-Barberio et al. Oncotarget
- The Histone Methyltransferase Ezh2 Controls Mechanisms of Adaptive Resistance to Tumor Immunotherapy
- (2017) Daniel Zingg et al. Cell Reports
- Epigenetic modifications of the immune-checkpoint genes CTLA4 and PDCD1 in non-small cell lung cancer results in increased expression
- (2017) Sebastian Marwitz et al. Clinical Epigenetics
- The prognostic value of cytotoxic T-lymphocyte antigen 4 in cancers: a systematic review and meta-analysis
- (2017) Pingping Hu et al. Scientific Reports
- CTLA-4 and PD-1 Pathways
- (2016) Elizabeth I. Buchbinder et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Negative regulation of TIM-3 expression in AML cell line (HL-60) using miR-330-5p
- (2016) Haniyeh Fooladinezhad et al. BRITISH JOURNAL OF BIOMEDICAL SCIENCE
- Combining Epigenetic and Immunotherapy to Combat Cancer
- (2016) Katherine B. Chiappinelli et al. CANCER RESEARCH
- HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma
- (2016) Hong Zheng et al. CLINICAL CANCER RESEARCH
- High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis
- (2016) Fabian Finkelmeier et al. EUROPEAN JOURNAL OF CANCER
- Serum levels of soluble programmed cell death ligand 1 as a prognostic factor on the first-line treatment of metastatic or recurrent gastric cancer
- (2016) Naoki Takahashi et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- PD-L1 (CD274) promoter methylation predicts survival in patients with acute myeloid leukemia
- (2016) D Goltz et al. LEUKEMIA
- Histone Modifications and Cancer
- (2016) James E. Audia et al. Cold Spring Harbor Perspectives in Biology
- miR-424(322) reverses chemoresistance via T-cell immune response activation by blocking the PD-L1 immune checkpoint
- (2016) Shaohua Xu et al. Nature Communications
- Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
- (2016) Shohei Koyama et al. Nature Communications
- The tumor suppressor miR-138-5p targets PD-L1 in colorectal cancer
- (2016) Lian Zhao et al. Oncotarget
- miR-28 modulates exhaustive differentiation of T cells through silencing programmed cell death-1 and regulating cytokine secretion
- (2016) Qing Li et al. Oncotarget
- Histone acetyltransferases: challenges in targeting bi-substrate enzymes
- (2016) Hannah Wapenaar et al. Clinical Epigenetics
- Higher preoperative serum levels of PD-L1 and B7-H4 are associated with invasive and metastatic potential and predictable for poor response to VEGF-targeted therapy and unfavorable prognosis of renal cell carcinoma
- (2016) Takehiko Fukuda et al. Cancer Medicine
- PD-L1 (CD274) promoter methylation predicts survival in colorectal cancer patients
- (2016) Diane Goltz et al. OncoImmunology
- Adaptive resistance to anti-PD1 therapy by Tim-3 upregulation is mediated by the PI3K-Akt pathway in head and neck cancer
- (2016) Gulidanna Shayan et al. OncoImmunology
- Targeting epigenetic regulations in cancer
- (2015) Bo Ning et al. ACTA BIOCHIMICA ET BIOPHYSICA SINICA
- MicroRNAs in cancer: from developmental genes in worms to their clinical application in patients
- (2015) M Pichler et al. BRITISH JOURNAL OF CANCER
- Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses
- (2015) Katherine B. Chiappinelli et al. CELL
- Phase I/II Study of Azacitidine, Docetaxel, and Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Therapy
- (2015) Rakesh Singal et al. Clinical Genitourinary Cancer
- Tim-3 fosters HCC development by enhancing TGF-β-mediated alternative activation of macrophages
- (2015) Wenjiang Yan et al. GUT
- PDL1 Regulation by p53 via miR-34
- (2015) Maria Angelica Cortez et al. JNCI-Journal of the National Cancer Institute
- MiR-138 exerts anti-glioma efficacy by targeting immune checkpoints
- (2015) Jun Wei et al. NEURO-ONCOLOGY
- Identification of lncRNA-associated competing triplets reveals global patterns and prognostic markers for cancer
- (2015) Peng Wang et al. NUCLEIC ACIDS RESEARCH
- DNMT1-dependent suppression of microRNA424 regulates tumor progression in human bladder cancer
- (2015) Chun-Te Wu et al. Oncotarget
- PDL1 Regulation by p53 via miR-34
- (2015) Maria Angelica Cortez et al. JNCI-Journal of the National Cancer Institute
- Decitabine Enhances Lymphocyte Migration and Function and Synergizes with CTLA-4 Blockade in a Murine Ovarian Cancer Model
- (2015) L. Wang et al. Cancer Immunology Research
- Galectin-3 Shapes Antitumor Immune Responses by Suppressing CD8+ T Cells via LAG-3 and Inhibiting Expansion of Plasmacytoid Dendritic Cells
- (2015) T. Kouo et al. Cancer Immunology Research
- HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade
- (2015) D. M. Woods et al. Cancer Immunology Research
- PD-1 blockade upregulate TIM-3 expression as a compensatory regulation of immune check point receptors in HNSCC TIL
- (2015) Gulidanna Shayan et al. Journal for ImmunoTherapy of Cancer
- Inducible but Not Constitutive Expression of PD-L1 in Human Melanoma Cells Is Dependent on Activation of NF-κB
- (2015) Kavitha Gowrishankar et al. PLoS One
- The Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8 + T Cell Effector Function
- (2014) Robert J. Johnston et al. CANCER CELL
- TET family proteins: new players in gliomas
- (2014) Er-Bao Bian et al. JOURNAL OF NEURO-ONCOLOGY
- High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial
- (2014) D Rossille et al. LEUKEMIA
- Cancer Epigenetics: Tumor Heterogeneity, Plasticity of Stem-like States, and Drug Resistance
- (2014) Hariharan Easwaran et al. MOLECULAR CELL
- Epigenomic alterations define lethal CIMP-positive ependymomas of infancy
- (2014) S. C. Mack et al. NATURE
- Circulating Programmed Death-1 as a Marker for Sustained High Hepatitis B Viral Load and Risk of Hepatocellular Carcinoma
- (2014) Hsiang-Yun Cheng et al. PLoS One
- Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells
- (2014) K. Kim et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Erasers of Histone Acetylation: The Histone Deacetylase Enzymes
- (2014) E. Seto et al. Cold Spring Harbor Perspectives in Biology
- DNA Methylation in Mammals
- (2014) E. Li et al. Cold Spring Harbor Perspectives in Biology
- Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression
- (2014) Limo Chen et al. Nature Communications
- Immune regulatory effects of panobinostat in patients with Hodgkin lymphoma through modulation of serum cytokine levels and T-cell PD1 expression
- (2014) Y Oki et al. Blood Cancer Journal
- Tim-3: An Emerging Target in the Cancer Immunotherapy Landscape
- (2014) A. C. Anderson Cancer Immunology Research
- The anticancer effects of HDAC inhibitors require the immune system
- (2014) Alison C West et al. OncoImmunology
- Progress and challenge of microRNA research in immunity
- (2014) Hyang-Mi Lee et al. Frontiers in Genetics
- The role of genetics in the establishment and maintenance of the epigenome
- (2013) Covadonga Huidobro et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Epigenetic modulation of the immune function
- (2013) Beatriz Suárez-Álvarez et al. Epigenetics
- MicroRNA-138 suppresses ovarian cancer cell invasion and metastasis by targeting SOX4 and HIF-1α
- (2013) Yu-Ming Yeh et al. INTERNATIONAL JOURNAL OF CANCER
- The critical importance of epigenetics in autoimmunity
- (2013) Qianjin Lu JOURNAL OF AUTOIMMUNITY
- Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents
- (2013) H Yang et al. LEUKEMIA
- The antimelanoma activity of the histone deacetylase inhibitor panobinostat (LBH589) is mediated by direct tumor cytotoxicity and increased tumor immunogenicity
- (2013) David M. Woods et al. MELANOMA RESEARCH
- Epigenetic regulation and cancer (Review)
- (2013) Q.W. CHEN et al. ONCOLOGY REPORTS
- SET for life: biochemical activities and biological functions of SET domain-containing proteins
- (2013) Hans-Martin Herz et al. TRENDS IN BIOCHEMICAL SCIENCES
- Cancer Genetics and Epigenetics: Two Sides of the Same Coin?
- (2012) Jueng Soo You et al. CANCER CELL
- SnapShot: Histone Lysine Methylase Complexes
- (2012) Man Mohan et al. CELL
- Programmed Death Ligand 2 in Cancer-Induced Immune Suppression
- (2012) Esdy N. Rozali et al. Clinical & Developmental Immunology
- Global DNA hypomethylation in cancer: review of validated methods and clinical significance
- (2012) Estela G. Toraño et al. CLINICAL CHEMISTRY AND LABORATORY MEDICINE
- Tim-3, a negative regulator of anti-tumor immunity
- (2012) Ana Carrizosa Anderson CURRENT OPINION IN IMMUNOLOGY
- Tet family proteins and 5-hydroxymethylcytosine in development and disease
- (2012) L. Tan et al. DEVELOPMENT
- Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma
- (2012) Hang Li et al. HEPATOLOGY
- Assessing sample and miRNA profile quality in serum and plasma or other biofluids
- (2012) Thorarinn Blondal et al. METHODS
- A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells
- (2012) Sarah K Knutson et al. Nature Chemical Biology
- Class I Histone Deacetylase Inhibitor Entinostat Suppresses Regulatory T Cells and Enhances Immunotherapies in Renal and Prostate Cancer Models
- (2012) Li Shen et al. PLoS One
- A Soluble Form of CTLA-4 Is Present in Paediatric Patients with Acute Lymphoblastic Leukaemia and Correlates with CD1d+ Expression
- (2012) Rita Simone et al. PLoS One
- miR-34 – a microRNA replacement therapy is headed to the clinic
- (2012) Andreas G. Bader Frontiers in Genetics
- MicroRNAs and the cell cycle
- (2011) María José Bueno et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
- Histone deacetylase inhibitors, valproic acid and trichostatin-A induce apoptosis and affect acetylation status of p53 in ERG-positive prostate cancer cells
- (2011) E. Reddy INTERNATIONAL JOURNAL OF ONCOLOGY
- Thymine DNA Glycosylase Can Rapidly Excise 5-Formylcytosine and 5-Carboxylcytosine
- (2011) Atanu Maiti et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- DNA methylation in cancer development, diagnosis and therapy--multiple opportunities for genotoxic agents to act as methylome disruptors or remediators
- (2011) J. Lewandowska et al. MUTAGENESIS
- The Polycomb complex PRC2 and its mark in life
- (2011) Raphaël Margueron et al. NATURE
- Cancer epigenetics reaches mainstream oncology
- (2011) Manuel Rodríguez-Paredes et al. NATURE MEDICINE
- The histone deacetylase inhibitors vorinostat and romidepsin downmodulate IL-10 expression in cutaneous T-cell lymphoma cells
- (2010) CE Tiffon et al. BRITISH JOURNAL OF PHARMACOLOGY
- Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer
- (2010) Siqing Fu et al. CANCER
- Dissecting DNA hypermethylation in cancer
- (2010) Marcos R.H. Estécio et al. FEBS LETTERS
- Identification of new markers discriminating between myeloid and lymphoid acute leukemia
- (2010) Houda Haouas et al. Hematology
- LAG-3 Expression Defines a Subset of CD4+CD25highFoxp3+ Regulatory T Cells That Are Expanded at Tumor Sites
- (2010) C. Camisaschi et al. JOURNAL OF IMMUNOLOGY
- Human LSD2/KDM1b/AOF1 Regulates Gene Transcription by Modulating Intragenic H3K4me2 Methylation
- (2010) Rui Fang et al. MOLECULAR CELL
- DNMT3AMutations in Acute Myeloid Leukemia
- (2010) Timothy J. Ley et al. NEW ENGLAND JOURNAL OF MEDICINE
- Will DNA methylation inhibitors work in solid tumors? A review of the clinical experience with azacitidine and decitabine in solid tumors
- (2010) Lisa A Cowan et al. Epigenomics
- Epigenetic mechanisms and genome stability
- (2010) Emily L. Putiri et al. Clinical Epigenetics
- Global Levels of Histone Modifications Predict Prognosis in Different Cancers
- (2009) David B. Seligson et al. AMERICAN JOURNAL OF PATHOLOGY
- Mutations of polycomb-associated geneASXL1in myelodysplastic syndromes and chronic myelomonocytic leukaemia
- (2009) Véronique Gelsi-Boyer et al. BRITISH JOURNAL OF HAEMATOLOGY
- MicroRNA-138 suppresses invasion and promotes apoptosis in head and neck squamous cell carcinoma cell lines
- (2009) Xiqiang Liu et al. CANCER LETTERS
- Epigenetics in cancer
- (2009) S. Sharma et al. CARCINOGENESIS
- Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer
- (2009) Gijs van Haaften et al. NATURE GENETICS
- Mutation inTET2in Myeloid Cancers
- (2009) François Delhommeau et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lysine Acetylation Targets Protein Complexes and Co-Regulates Major Cellular Functions
- (2009) C. Choudhary et al. SCIENCE
- Conversion of 5-Methylcytosine to 5-Hydroxymethylcytosine in Mammalian DNA by MLL Partner TET1
- (2009) M. Tahiliani et al. SCIENCE
- DNA hypomethylation in cancer cells
- (2009) Melanie Ehrlich Epigenomics
- PD-1 and Its Ligands in Tolerance and Immunity
- (2008) Mary E. Keir et al. Annual Review of Immunology
- LNA-mediated microRNA silencing in non-human primates
- (2008) Joacim Elmén et al. NATURE
- The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells
- (2008) Xin Yu et al. NATURE IMMUNOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started